晚期卵巢癌患者血浆与卵巢组织鞘脂谱分析
研究纳入74例卵巢癌患者,采用液相色谱串联质谱检测血浆C16-Cer、C18:1-Cer和C18-Cer,采用超高效液相色谱串联质谱检测组织鞘脂。晚期卵巢癌患者血浆三种神经酰胺及卵巢组织五种神经酰胺和S1P浓度均高于对照组,部分血浆神经酰胺超过特定阈值时卵巢癌风险显著升高。
要点
- 晚期卵巢癌患者血浆C16-Cer、C18:1-Cer、C18-Cer浓度显著高于对照组。
- 卵巢组织中C16-Cer、C18:1-Cer、C18-Cer、C24:1-Cer、C24-Cer及S1P浓度显著升高。
- 血浆C16-Cer>311.88ng/100μl、C18:1-Cer>4.75ng/100μl、C18-Cer>100.76ng/100μl时卵巢癌风险显著升高。
核心结论
- 生物活性鞘脂在癌症发生发展及转移过程中发挥重要作用,部分鞘脂可作为晚期卵巢癌的潜在生物标志物并参与其发病机制。
研究设计与样本
- 研究纳入74例卵巢癌患者,采用LC/MS/MS检测血浆C16-Cer、C18:1-Cer和C18-Cer浓度,采用UHPLC/MS/MS检测卵巢组织鞘脂含量。
主要发现
- 晚期卵巢癌患者血浆C16-Cer、C18:1-Cer、C18-Cer浓度较对照组显著升高,P值分别为0.031、0.022、0.020。
- 晚期卵巢癌患者卵巢组织中C16-Cer、C18:1-Cer、C18-Cer、C24:1-Cer、C24-Cer浓度较健康个体显著升高,P值分别为0.025、0.049、0.032、0.005、0.013。
- 晚期卵巢癌患者卵巢组织中S1P浓度较健康个体显著升高,P=0.004。
- 血浆C16-Cer>311.88ng/100μl时卵巢癌风险显著升高,AUC为0.76,P=0.0261。
- 血浆C18:1-Cer>4.75ng/100μl时卵巢癌风险显著升高,AUC为0.77,P=0.0160;血浆C18-Cer>100.76ng/100μl时风险显著升高,AUC为0.77,P=0.0136。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of lipids in carcinogenesis through induction of abnormal cell lines in the human body is currently undisputable. Based on the literature, bioactive sphingolipids play an essential role in the development and progression of cancer and are involved in the metastatic process. The aim of this study was to determine the concentration of selected sphingolipids in patients with advanced ovarian cancer (AOC, FIGO III/IV, high grade ovarian cancer). METHODS: Seventy-four patients with ovarian cancer were enrolled. Plasma concentrations of C16-Cer, C18:1-Cer and C18-Cer were assessed by LC/MS/MS. The content of tissue sphingolipids was measured using a UHPLC/MS/MS. RESULTS: Plasma concentration of 3 ceramides: C16-Cer, C18:1-Cer and C18-Cer was significantly elevated in women with advanced ovarian cancer compared to control group (P=0.031; 0.022; 0.020; respectively). There were increases in concentration of 5 ceramides: C16-Cer, C18:1-Cer, C18-Cer, C24:1-Cer, C24-Cer (P=0.025; 0.049; 0.032; 0.005; 0.013, respectively) and S1P (P=0.004) in ovarian tissue of women with advanced ovarian cancer compared to healthy individuals. Importantly, significantly higher risk of ovarian cancer when the plasma concentration of C16-Cer>311.88ng/100μl (AUC: 0.76, P=0.0261); C18:1-Cer>4.75ng/100μl (AUC: 0.77, P=0.0160) and C18-Cer>100.76ng/100μl (AUC:0.77, P=0.0136) was noticed. CONCLUSIONS: Bioactive sphingolipids play an essential role in the development and progression of cancer and they also take part in the process of metastasizing. This study suggests that some sphingolipids can be used as potential biomarkers of advanced ovarian cancer and that they can play an important role in the pathogenesis of this disease.
引用
- Knapp P, Bodnar L, Błachnio-Zabielska A, et al. Plasma and ovarian tissue sphingolipids profiling in patients with advanced ovarian cancer. Gynecol Oncol. 2017. PMID: 28800942. doi:10.1016/j.ygyno.2017.07.143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。